The MHC class I and II antigen processing and presentation pathways display peptides to
circulating CD 8+ cytotoxic and CD 4+ helper T cells respectively to enable pathogens and …

Introduction: Chimeric antigen receptors (CARs) usually combine the antigen binding site of
a monoclonal antibody with the signal activating machinery of a T cell, freeing antigen …

Purpose Chimeric antigen receptor (CAR) engineered T-cells occupy an increasing niche in
cancer immunotherapy. In this context, CAR-mediated CD3ζ signaling is sufficient to elicit …

Lymphomas arise from clonal expansions of B, T, or NK cells at different stages of
differentiation. Because they occur in the immunocyte-rich lymphoid tissues, they are easily …

The uptake, transport, and presentation of Ags by lung dendritic cells (DCs) are central to the
initiation of CD8 T cell responses against respiratory viruses. Although several studies have …

The immune system constantly monitors the emergence of cancerous cells and eliminates
them. CD8+ cytotoxic T lymphocytes (CTLs), which kill tumor cells and provide antitumor …

Background The proteome is an important reservoir of potential therapeutic targets for
cancer. This study aimed to examine the causal associations between plasma proteins and …

Defects in MHC-I antigen presentation represent a common feature of cancer and allow
evasion from T cell recognition. Recent findings from immunotherapy in melanoma …

TAP1-TAP2 heterodimeric complexes are recognized as the transporter associated with
antigen processing of major histocompatibility complex class I peptides for recognition by …

Emerging cancers are sculpted by neo-Darwinian selection for superior growth and survival
but minimal immunogenicity; consequently, metastatic cancers often evolve common genetic …